Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01754987 · ClinicalTrials.gov registry record · Phase 1

A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective

A Phase 1 study of Metastatic Hepatocellular Carcinoma and Advanced Liver Cancer, sponsored by Thomas Jefferson University.

Completed
Registry status
Phase 1
Development phase
5
Enrollment target
1
Study location

NCT01754987: Completed Phase 1 study of Metastatic Hepatocellular Carcinoma and Advanced Liver Cancer, sponsored by Thomas Jefferson University.

NCT01754987 is a Phase 1 study of Metastatic Hepatocellular Carcinoma and Advanced Liver Cancer that has completed, run by Thomas Jefferson University. The registered enrollment target is 5 participants, below the 103-participant average among 11 other Metastatic Hepatocellular Carcinoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01754987, a Phase 1 study of Metastatic Hepatocellular Carcinoma and Advanced Liver Cancer, has completed, sponsored by Thomas Jefferson University.

COMPLETED
Registry status
Phase 1
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with sorafenib versus treatment with sorafenib alone in subjects with metastatic hepatocellular carcinoma. The phase I aspect will assess the safety and efficacy of the concurrent treatments and the phase II aspect will utilize CT (computer-tomography) scans to assess overall tumor response rate and evaluate disease progression

Primary Outcome

The primary aim is to assess whether or not (IV) Ascorbic Acid (AA) with sorafenib therapy is relatively safe and well-tolerated according to Common Terminology Criteria for Adverse Events (CTCAE)v4.0

Interventions

  • DRUG Sorafenib
  • DRUG Ascorbic Acid + Sorafenib

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2012-09
Est. Completion 2016-01
Phase Phase 1
Thomas Jefferson University

292 total trials

What the finished NCT01754987 record still lists

NCT01754987 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 103-participant average among 11 other Metastatic Hepatocellular Carcinoma trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Metastatic Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Sorafenib is the first listed.

NCT01754987 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01754987 about?

NCT01754987 is a clinical study titled "A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective". This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with sorafenib versus treatment with sorafenib alone in subjects with metastatic hepatocellular carcinoma. The phase I aspect will assess the safety and efficacy of the concurrent treatments and the phase II...

What is the current status of trial NCT01754987?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2012-09. Estimated completion is 2016-01.

What conditions does trial NCT01754987 study?

This clinical trial studies the following conditions: Metastatic Hepatocellular Carcinoma, Advanced Liver Cancer.

What interventions are being tested in trial NCT01754987?

The interventions under investigation include: Sorafenib (DRUG), Ascorbic Acid + Sorafenib (DRUG).

Who is sponsoring clinical trial NCT01754987?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01754987 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01754987's enrollment target sits among peer trials

5 12th of 11 the lowest of 11 other Metastatic Hepatocellular Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01754987, the US trial registry maintained by the National Library of Medicine. NCT01754987 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.